Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
31 hedge funds and large institutions have $47.2M invested in Elevation Oncology in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 9 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
1.84% more ownership
Funds ownership: 78.79% → 80.62% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
11% less funds holding
Funds holding: 35 → 31 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
57% less capital invested
Capital invested by funds: $110M → $47.2M (-$63M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.81M |
| 2 |
SCM
Sio Capital Management
New York
|
+$440K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$227K |
| 4 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$120K |
| 5 |
B
Bailard
Foster City,
California
|
+$94.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.65M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$132K |
| 3 |
Jane Street
New York
|
-$126K |
| 4 |
Janus Henderson Group
London,
|
-$118K |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$86K |
ELEV Hedge Fund Activity: Q1 2022 in Review
31 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q1 2022, worth a combined $47.2M — down 57% from $110M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ELEV and 5 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was BVF Inc, adding an estimated $2.81M. The largest seller was Driehaus Capital Management, cutting an estimated $1.65M.
- 31 institutional investors held Elevation Oncology (ELEV) as of Q1 2022, down from 35 in Q4 2021.
- Funds reported $47.2M of Elevation Oncology stock for Q1 2022, down 57% quarter-over-quarter.
- 5 funds opened new Elevation Oncology positions in Q1 2022 and 9 closed out, a net change of -4 holders.
- The largest Elevation Oncology buyer in Q1 2022 was BVF Inc, an estimated $2.81M added.
- The largest Elevation Oncology seller in Q1 2022 was Driehaus Capital Management, an estimated $1.65M sold.
Based on aggregated 13F filings for Q1 2022.